Trial intelligence / Profile preview

Antineoplastons A10 and AS2-1 in Advanced Head and Neck Cancer

NCT00003489Phase 2Terminated

Sponsor
Burzynski Research Institute
Start
May 1996
Primary completion
Apr 1998
Modality
Peptides, Small Molecules
Countries
1
01

Overview

A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in head and neck cancer (HNC), sponsored by Burzynski Research Institute. Started May 1996; status: terminated.

02

Drugs

antineoplaston A10antineoplaston AS2-1
03

Conditions

head and neck cancer (HNC)

Beyond the preview

Go deeper on NCT00003489.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00003489.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call